https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1663 50 : 1 noted. All analogues were screened for their ability to interact with CRH₁ and CRH₂ receptors. In all instances only poor agonistic and/or antagonistic behaviour was noted at CRH₂. However, several compounds were potent and selective CRH₁ antagonists, most notably 13a Ki = 39nM. Additionally we have utilized these data and that recently reported by others to refine our original CRH₁ pharmacophore.]]> Sat 24 Mar 2018 08:30:27 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:3267 Sat 24 Mar 2018 07:21:22 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46586 in vitro, in vivo and epidemiological studies involving PM containing Fe or iron oxide following inhalation or instillation. The major findings from these investigations are summarized and tabulated. Epidemiological studies showed that exposure to Fe oxide is correlated with an increased incidence of cancer, cardiovascular diseases, and several respiratory diseases. Iron PM was found to induce inflammatory effects in vitro and in vivo and to translocate to remote locations including the brain following inhalation. A potential pathway for the PM-containing Fe-mediated toxicity by inhalation is via the generation of ROS which leads to lipid peroxidation and DNA and protein oxidation. Our recommendations include an expansion of epidemiological, in vivo and in vitro studies, integrating research improvements outlined in this review, such as the method of particle preparation, cell line type, and animal model, to enhance our understanding of the complex biological interactions of these particles.]]> Fri 25 Nov 2022 14:47:06 AEDT ]]>